STOCKHOLM, June 22, 2022 /PRNewswire/ -- Devyser has been awarded a tender from Héma-Québec, in Québec, Canada, for its non-invasive fetal RHD detection product, used to determine fetal RHD status from maternal plasma in early pregnancy. The tender is initially valid over three years starting in 2023, with a potential extension of two additional years. The total possible order value amounts to just over 16 MSEK.
"This is a strategic breakthrough in the North American market, and I am very proud of the entire team who made this happen", says CEO Fredrik Alpsten. "National and regional screening programs represent an important upside for us, and this award is a true confirmation of our products competitiveness in these large international tenders."
Devyser has submitted a regulatory registration application of the RHD product in Canada as part of the tender process. The company already holds an MDSAP certification since 2020, which is a requirement for registration of products in Canada.
The award is subject to a testing period for verification and validation during the first half of 2023 and the first order from the tender is expected around mid-2023 once the final award contract is in place.
The Devyser RHD product is used by clinical labs for non-invasive determination of fetal RHD status in maternal plasma as early as gestation week 10. Devyser's unique technology significantly simplifies laboratory workflows and analysis. It also enables increased throughput and shortened turnaround times for the labs. Determining the fetal RHD status is important in pregnant women who are RHD-negative in order to avoid hemolytic disease, a condition that can be life-threatening for the newborn baby. Hemolytic disease of the fetus can be prevented by RHD determination combined with prophylactic treatment during pregnancy.
Héma-Québec's mission is to efficiently meet the Québec population's needs for blood and other high-quality biological products of human origin. Héma-Québec has over 1,400 employees, nearly 200,000 donors of blood, stem cells, mother's milk and human tissues, as well as thousands of blood drive volunteers. Every year, Héma-Québec delivers over 800,000 biological products of human origin to Québec's hospitals in order to meet patients' needs.
This information is information that Devyser Diagnostics AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation 596/2014. The information was submitted for publication, through the agency of the contact persons below, on June 22, 2022, at 10:30 CET.
For more information, please contact:
Fredrik Alpsten, CEO E-mail: firstname.lastname@example.org Tel: +46 706 673 106
Sabina Berlin CFOE-post: email@example.comTel: +46 739 519 502
About Devyser Diagnostics AB (publ)
Devyser is specialized in the development, manufacture, and sales of diagnostic kits. The products are sold to routine diagnostic laboratories in more than 45 countries. The products are used for advanced DNA testing in the hereditary disease, oncology and post-transplantation monitoring fields, to enable targeted cancer treatment, the diagnosis of a large number of genetic diseases, and transplant patient follow-up. Devyser's product development focuses on simplifying and streamlining advanced testing processes to improve throughput, reduce hands-on time and produce accurate and trusted results. Devyser was founded in 2004 and is based in Stockholm, Sweden.
Devyser's shares are listed on Nasdaq First North Growth Market Stockholm (ticker: DVYSR). The company's Certified Adviser is Redeye AB, e-mail address firstname.lastname@example.org and telephone number +46 8 121 576 90. For more information, visit www.devyser.com.
This information was brought to you by Cision http://news.cision.com
The following files are available for download: